Globus Medical, Inc. (NYSE:GMED) Receives $104.36 Average Target Price from Analysts

Globus Medical, Inc. (NYSE:GMED) has been given a consensus rating of “Moderate Buy” by the sixteen research firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $104.3636.

Several analysts have recently issued reports on GMED shares. Citigroup reiterated a “market perform” rating on shares of Globus Medical in a research note on Thursday, January 8th. Piper Sandler restated an “overweight” rating and set a $115.00 price target (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. TD Cowen raised shares of Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research note on Wednesday, February 25th. Finally, Wall Street Zen raised shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd.

Globus Medical Price Performance

Shares of NYSE GMED opened at $84.81 on Friday. The company has a 50-day moving average price of $90.71 and a 200-day moving average price of $78.49. The stock has a market capitalization of $11.47 billion, a P/E ratio of 21.52, a P/E/G ratio of 1.99 and a beta of 1.05. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.84 EPS. As a group, equities research analysts anticipate that Globus Medical will post 3.44 earnings per share for the current fiscal year.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Insider Activity at Globus Medical

In other news, Director Leslie V. Norwalk sold 2,000 shares of Globus Medical stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the sale, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. The trade was a 16.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 35,594 shares of company stock valued at $3,332,253. 18.54% of the stock is owned by insiders.

Institutional Trading of Globus Medical

Large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its stake in shares of Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Burgundy Asset Management Ltd. lifted its stake in Globus Medical by 24.3% in the second quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after purchasing an additional 679,691 shares during the last quarter. Bank of Montreal Can lifted its stake in Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. William Blair Investment Management LLC grew its holdings in Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after purchasing an additional 414,134 shares during the period. Finally, Sculptor Capital LP grew its holdings in Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.